LVTX
Income statement / Annual
Last year (2023), LAVA Therapeutics N.V.'s total revenue was $6.77 M,
a decrease of 65.09% from the previous year.
In 2023, LAVA Therapeutics N.V.'s net income was -$41.97 M.
See LAVA Therapeutics N.V.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
| Operating Revenue |
$6.77 M
|
$19.39 M
|
$5.35 M
|
$3.75 M
|
$0.00
|
| Cost of Revenue |
$3.48 M |
$0.00 |
$0.00 |
$15.70 M |
$8.35 M |
| Gross Profit |
$3.29 M |
$19.39 M |
$5.35 M |
-$11.95 M |
-$8.35 M |
| Gross Profit Ratio |
0.49 |
1 |
1 |
-3.19 |
0 |
| Research and Development
Expenses |
$33.81 M
|
$40.11 M
|
$36.95 M
|
$15.70 M
|
$8.35 M
|
| General & Administrative
Expenses |
$12.73 M
|
$14.12 M
|
$12.02 M
|
$2.72 M
|
$1.24 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$12.73 M
|
$14.12 M
|
$12.02 M
|
$2.72 M
|
$1.24 M
|
| Other Expenses |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Operating Expenses |
$46.54 M |
$51.31 M |
$46.92 M |
$3.59 M |
$1.25 M |
| Cost And Expenses |
$50.02 M |
$51.31 M |
$46.92 M |
$19.29 M |
$9.60 M |
| Interest Income |
$2.97 M |
$257,000.00 |
$625,000.00 |
$342,000.00 |
$86,000.00 |
| Interest Expense |
$0.00 |
$0.00 |
$625,000.00 |
$342,000.00 |
$0.00 |
| Depreciation &
Amortization |
$1.28 M
|
$504,000.00
|
$331,000.00
|
$213,000.00
|
$99,000.00
|
| EBITDA |
-$40.42 M
|
-$30.88 M
|
-$41.02 M
|
-$14.65 M
|
-$9.48 M
|
| EBITDA Ratio |
-5.97 |
-1.77 |
-8.09 |
-3.86 |
0 |
| Operating Income Ratio
|
-6.39
|
-1.8
|
-8.15
|
-3.92
|
0
|
| Total Other
Income/Expenses Net |
$1.56 M
|
$3.18 M
|
$1.42 M
|
-$1.21 M
|
-$104,000.00
|
| Income Before Tax |
-$41.70 M |
-$31.66 M |
-$42.20 M |
-$15.88 M |
-$9.69 M |
| Income Before Tax Ratio
|
-6.16
|
-1.63
|
-7.89
|
-4.24
|
0
|
| Income Tax Expense |
$279,000.00 |
$249,000.00 |
$157,000.00 |
$43,000.00 |
$0.00 |
| Net Income |
-$41.97 M |
-$31.91 M |
-$42.36 M |
-$15.93 M |
-$9.69 M |
| Net Income Ratio |
-6.2 |
-1.65 |
-7.92 |
-4.25 |
0 |
| EPS |
-1.57 |
-1.23 |
-2.14 |
-39.9 |
-21.65 |
| EPS Diluted |
-1.57 |
-1.23 |
-2.14 |
-39.9 |
-21.65 |
| Weighted Average Shares
Out |
$26.73 M
|
$25.92 M
|
$19.76 M
|
$25.35 M
|
$18.41 M
|
| Weighted Average Shares
Out Diluted |
$26.73 M
|
$25.92 M
|
$19.76 M
|
$25.35 M
|
$18.41 M
|
| Link |
|
|
|
|
|
